Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Altretamine Hexalen 50 mg Chemotherapy Alkylating Agent Triazines Yes 1990 2019 In Use
NA Afatinib Gliotrif 30 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Abemaciclib Verzenio 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Afatinib Gliotrif 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Apalutamide Erleada 60mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2018 In Use
NA Alectinib Alecensa 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2015 In Use
NA Aprepitant Emend 40 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Aprepitant Emend 80 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Aprepitant Emend 125 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Abemaciclib Verzenio 100 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Avapritinib Ayvakit 300mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
Adagrasib Krazati 200mg Immunotherapy RAS Inhibitor KrAS G12C Yes 2022 In Use
NA Belumosudil Rezurock 200mg Chemotherapy Rho Kinase Inhibitor ROCK1, ROCK2 Yes 2021 In Use
NA Axitinib Axitinib 5 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Alitretinoin Panretin 0.10% Hormonal Therapy Immunomodulator Retinoic Acid Derivative No 1999 In Use
NA Abemaciclib Verzenio 150 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Capmatinib Tabrecta 150mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2020 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.